Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3341-3360 of 3,900 trials

Autoimmune Uveitis: Probiotic Supplement Study

We are studying the effects of a probiotic on people with autoimmune uveitis to see if it improves vision and reduces inflammation. The trial will also check the safety of this treatment.

Autoimmune Uveitis1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesOphthalmology

Blood Cancer Treatment: SMART101 After Stem Cell Transplant

We are studying the safety and effectiveness of SMART101 for patients with blood cancers after stem cell transplantation. The goal is to see if it helps improve immune recovery and reduce complications.

Allogenic Stem Cell Transplantation>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyInfectious Diseases

Alzheimer’s Disease: NTRX-07 Treatment Study

We are investigating the safety and tolerability of NTRX-07 in people with mild cognitive impairment or mild to moderate Alzheimer's disease. This study aims to understand how well the treatment works and its effects on patients.

Mild Cognitive Impairment (MCI)Mild to Moderate Alzheimer's Disease (AD)≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesNeurology

Leukemia Treatment: Ponatinib vs. Imatinib

We are studying whether ponatinib combined with chemotherapy is as effective as imatinib for adults with Philadelphia-Chromosome positive acute lymphoblastic leukemia. The trial also evaluates treatment outcomes for patients who respond differently.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Non-Small Cell Lung Cancer: Sigvotatug Vedotin with Pembrolizumab

We are studying a new treatment combining sigvotatug vedotin with pembrolizumab for patients with advanced non-small cell lung cancer that has high PD-L1 levels. The goal is to see if this combination works better than pembrolizumab alone.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Cardiac Amyloidosis: PET Imaging with Vizamyl®

We are studying a new imaging tracer to see how effectively it detects amyloid deposits in the hearts of patients with cardiac amyloidosis. This research may help improve diagnosis and understanding of the disease.

Cardiac Amyloidosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiology

Warm Autoimmune Hemolytic Anemia: Rilzabrutinib Study

We are investigating whether the oral medication rilzabrutinib can improve hemoglobin levels and reduce symptoms in adults with warm autoimmune hemolytic anemia. This study will also assess its safety compared to a placebo.

Autoimmune Hemolytic Anemia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesHematologyInternal Medicine

Chronic Migraine: CGRP Monoclonal Antibody and Botox Combination Therapy

We are investigating whether a combination of CGRP monoclonal antibodies and Botox can reduce the number of migraine days for adults with chronic migraines. This study compares the effects of this dual therapy to a single treatment with CGRP monoclonal antibodies.

Chronic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Essential Tremor: BP1.4979 Treatment Study

We are testing a new medication, BP1.4979, for adults with essential tremor to see if it helps reduce symptoms and improve quality of life. The study will also check how safe the treatment is for patients.

Essential Tremor1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

C3-Glomerulopathy: Testing CPV-104

We are examining the safety and how the body processes CPV-104 in healthy individuals and patients with C3-Glomerulopathy. This study aims to gather important information about this new treatment.

C3 Glomerulopathy1-2 yearsSafety phase (I)Nephrology

Premature Ejaculation: BP1.4979 Study

We are testing a new medication for adult men with primary premature ejaculation to see if it improves ejaculatory control and sexual satisfaction compared to a placebo.

Premature Ejaculation3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatryUrology

Turner Syndrome: Estrogen Therapy Comparison

We are studying the long-term effects of oral versus transdermal estrogen replacement therapy in women with Turner syndrome. This research aims to clarify health risks and benefits associated with each treatment method.

Turner's Syndrome6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

Metastatic Breast Cancer: Targeted Treatment Based on Genetic Analysis

We are studying whether targeted therapies guided by genetic testing can improve survival for patients with metastatic breast cancer compared to standard chemotherapy. This trial aims to personalize treatment based on individual genetic profiles.

Metastatic Breast CancerEfficacy phase (II)No PlaceboStandard MedicinesOncology

Oxytocin and Trust Learning in Attachment Development

We are exploring how oxytocin may influence trust learning and cognitive flexibility in a virtual reality setting. This study aims to understand its effects on social bonding and learning processes.

Healthy Children>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesPsychiatry

Hepatocellular Cancer and Lung Cancer: ABBV-324 vs. Lenvatinib

We are comparing an intravenous treatment to an oral medication for adults with hepatocellular cancer or squamous-cell lung cancer. The study aims to assess side effects and changes in disease activity.

Liver CancerNon-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Colorectal Cancer: Telisotuzumab Adizutecan Treatment

We are studying a new treatment for adults with colorectal cancer who have positive circulating tumor DNA but no visible disease. The goal is to see if this treatment improves disease-free survival compared to standard care.

Colorectal Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

HER2-Positive Cancer: Trastuzumab Deruxtecan Study

We are exploring a new treatment for HER2-positive cancer using a blood test to monitor changes in HER2 status. This study aims to improve treatment personalization and assess the safety of the new medication.

Metastatic HER2-Positive Breast CancerEfficacy phase (II)No PlaceboStandard MedicinesOncology

Septic Shock: Mesenchymal Stem Cells Treatment

We are studying whether early administration of mesenchymal stem cells can improve organ function in patients with septic shock. This trial compares the effects of MSCs to standard treatment in intensive care.

Severe Septic Shock>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInfectious DiseasesInternal MedicinePulmonology

DMT: Study in Healthy Volunteers

We are investigating the effects of DMT in healthy individuals to understand its safety and potential benefits. This research may help us learn more about how DMT works in the body.

Stroke>2 yearsSafety phase (I)Neurology

Ozone Therapy for Chemotherapy-Induced Pain Relief

We are studying whether adding ozone therapy helps cancer patients with painful neuropathy feel better and improve their quality of life. This trial will also look at the costs and safety of this treatment.

Chemotherapy-Induced Peripheral Neuropathy3-6 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesNeurologyOncology